公开(公告)号：EP1526140A4

公开(公告)日：2006-03-08

申请号：EP03766674

申请日：2003-07-31

申请人： ASTELLAS PHARMA INC

发明人： NOZAWA KATSURA ,  MOCHIZUKI SHINOBU

IPC分类号： A61P9/10 ,  A61P43/00 ,  C07K14/47 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/12 ,  G01N33/68 ,  A61K45/00 ,  C12N5/10 ,  C12P21/02 ,  C12Q1/02

CPC分类号： G01N33/6872 ,  C07K14/47 ,  G01N2500/00

摘要： It is intended to disclose a novel polypeptide; a polynucleotide encoding the above polypeptide; an expression vector containing the above polynucleotide; cells transfected with the above expression vector; a process for producing the above polypeptide; and a convenient screening method for obtaining a substance which is useful in treating cell injury or an inflammatory disease due to postischemic reperfusion. The above-described polypeptide is a potassium-dependent sodium-calcium exchanger expressed in peripheral leucocytes.

公开(公告)号：EP2261206A4

公开(公告)日：2011-08-17

申请号：EP09729006

申请日：2009-03-30

申请人： ASTELLAS PHARMA INC

发明人： KAKU HIDETAKA ,  TAKUWA TOMOFUMI ,  KAGEYAMA MICHIHITO ,  NOZAWA KATSURA ,  DOIHARA HITOSHI

IPC分类号： C07D209/34 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61P1/04 ,  A61P1/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D417/06

CPC分类号： C07D209/34 ,  C07D209/38 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D417/06

公开(公告)号：EP2072623A4

公开(公告)日：2009-12-30

申请号：EP07829360

申请日：2007-10-05

申请人： ASTELLAS PHARMA INC

发明人： NOZAWA KATSURA ,  SHODA ERI ,  DOIHARA HITOSHI ,  KOJIMA RYOSUKE

IPC分类号： C12Q1/02 ,  A61K45/00 ,  A61P1/00 ,  C12N5/10 ,  C12N15/09 ,  G01N33/15 ,  G01N33/50

CPC分类号： G01N33/6872 ,  G01N33/942 ,  G01N2500/10

公开(公告)号：EP1439235A4

公开(公告)日：2006-01-18

申请号：EP02758812

申请日：2002-08-08

申请人： ASTELLAS PHARMA INC

发明人： SANO YORIKATA ,  INAMURA KOHEI ,  MIYAKE AKIRA ,  YOKOI HIROMICHI ,  NOZAWA KATSURA ,  MOCHIZUKI SHINOBU

IPC分类号： C12N15/12 ,  G01N33/50 ,  G01N33/566 ,  C07K14/705

CPC分类号： G01N33/507 ,  G01N33/5008 ,  G01N33/566 ,  G01N2500/10 ,  G01N2510/00

摘要： It is intended to provide a method of screening a substance which inhibits cell death induced by the activation of PAPR, in particular, a substance which is useful as a remedy and/or a preventive for rheumatoid arthritis, nerve cell death in brain ischemia, heart cell death after arteriosclerosis reperfusion, autoimmune disruption of pancreatic islet b-cells, cell death following shock or inflammatory reaction due to immune cell death. Also, novel proteins and novel genes encoding the same are provided. The above screening method involves the step of bringing a test substance into contact with cells expressing LTRPC2 protein under conditions allowing the activation of the LTRPC2 protein, and the step of analyzing the inhibition of the activation of the LTRPC2 protein. The above-described novel proteins are rat and mouse LTRPC2 proteins, while the above novel genes are rat and mouse LTRPC2 genes.